The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~The use~~ A method of treating or preventing a disorder in which the blocking of purine receptors is beneficial, the method comprising administration to a subject in need of such treatment an effective dose of a compound of formula (1):



(I)

R_1 is H or NH_2;

R_2 is optionally substituted aryl or heteroaryl attached via a carbon atom;

R_3 is H; optionally substituted C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, or C_3-C_7 cycloalkyl, halogen; OH or OR_{10};

R_4 is H, optionally substituted C_1-C_6alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, C_3-C_7 cycloalkyl, aryl or heteroaryl,

R_5 is H or optionally substituted C_1-C_6 alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, or C_3-C_7 cycloalkyl;

or R_4 and R_5 together form a 5 or 6-membered heterocyclic ring;

R_{10} is optionally substituted C_1-C_6alkyl;

~~and~~ or a pharmaceutically acceptable ~~salts and prodrugs~~ salt or prodrug thereof, ~~in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors is beneficial,~~ PROVIDED THAT when R_2 is optionally substituted aryl ~~the said use is not the manufacture of a medicament for~~ method is not for the treatment or prevention of inflammatory pain.

2. (Currently Amended) The ~~use~~ method as claimed in claim 1 wherein R_2 is optionally

substituted phenyl.

3. (Currently Amended) The ~~use~~ method as claimed in claim 1 wherein R_2 is optionally substituted monocyclic or bicyclic heteroaryl.

4. (Currently Amended) The ~~use~~ method as claimed in claim 1 wherein R_2 is optionally substituted furyl, thienyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, indolyl or benzofuranyl.

5. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein optional substituents present in R_2 are selected from C_1-C_3 alkyl, C_1-C_3 alkoxy and carboxamide groups.

6. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 4~~ claim 1 wherein optional substituents present in R_2 are selected from methyl, ethyl, methoxy, ethoxy, cyano, chloro, bromo, fluoro, trifluoromethyl, and carboxamide groups $-CONR^AR^B$ where R^A and R^B are independently hydrogen, methyl or ethyl.

7. (Currently Amended) The ~~use~~ method as claimed in claim 1 wherein R_2 is 2-furyl, 5-methyl-2-furyl, 2-thlazolyl, 4methyl-2-thiazolyl, phenyl, 3-cyano-phenyl, or o-methyl-phenyl.

8. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein R_3 is H, C_1-C_6alkyl, C_3-C_6 cycloalkyl, halo substituted C_1-C_6alkyl, or halogen.

9. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 7~~ claim 1 wherein R_3 is H, methyl, ethyl, n- or isopropyl, cyclopropyl, no, sec- or tert-butyl, trifloromethyl, chloro, bromo or fluoro.

10. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein R4 is C_1-C_6alkyl, substituted by aryl or heteroaryl, the said aryl or heteroaryl ring being optionally substituted.

11. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 9~~ claim 1 wherein R_4 is arylmethyl or heteroarylmethyl, the said aryl or heteroaryl ring being optionally substituted.

12. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein R_4 is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted phenyl, pyridyl, furanyl, thienyl, isoxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, benzimidazolyl, indolyl, benzthiazolyl, benzthiadiazolyl, quinolyl, and isoquinolyl.

13. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 9~~ claim 1 wherein R_4 is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted phenyl, pyridyl, imidazolyl, pyrazolyl, and isoxazolyl.

14. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 10 to 13~~ claim 10 wherein optional substituents of R_4 are selected from C_1-C_6 alkyl, C_1-C_3 alkoxy, C_1-C_3 alkoxy-(C_1-C_3 alkyl)., chloro, bromo, fluoro, trifluoromethyl, $-NR^AR^B$, $-CONR^AR^B$, $-NR^ACOR^B$ where R^A and R^B are independently hydrogen or C_1-C_3 alkyl or together form an optionally substituted 5 or 6-membered heterocyclic ring.

15. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein R_5 is hydrogen.

16. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 9~~ claim 1 wherein R_4 and R_6 taken together with the nitrogen to which they are attached form a saturated 5 or 6-membered heterocyclic ring, optionally benzo-fused.

17. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 9~~ claim 1 wherein R_4 and R_5 taken together with the nitrogen to which they are attached form a dihydroindolyl, dihydroisoindolyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl ring system.

18. (Canceled)

19. (Currently Amended) A compound of formula (I) ~~as defined in any of claims 1 to 17,~~ (1):



(I)

R_1 is H or NH_2;

R_2 is optionally substituted aryl or heteroaryl attached via a carbon atom;

R_3 is H; optionally substituted C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, or C_3-C_7 cycloalkyl, halogen; OH or OR_{10};

R_4 is H, optionally substituted C_1-C_6alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, C_3-C_7 cycloalkyl, aryl or heteroaryl,

R_5 is H or optionally substituted C_1-C_6 alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, or C_3-C_7 cycloalkyl;

or R_4 and R_5 together form a 5 or 6-membered heterocyclic ring;

R_{10} is optionally substituted C_1-C_6alkyl;

or a pharmaceutically acceptable salt or prodrug thereof PROVIDED THAT: (a) R_2 is not an optionally substituted pyrazolopyridine ring system; and (b) when R_1 and R_3 are hydrogen and R_2 is unsubstituted phenyl then $-NR_4R_5$ is not $-NH_2$, $NHCH_3$ or $N(CH_3)_2$; and (c) when R_1 is $-NH_2$ and R_3 is hydrogen, then R_2 is not phenyl or phenyl substituted by one or more substituents selected from halogen, hydroxy, C_1-C_6 alkyl, C_1C_6 alkoxy, nitro, $-NH_2$, or-$NHCOCH_3$.

20. (Original)A compound as claimed in claim 19 wherein R_1 is $-NH_2$ and R_3 is hydrogen, and R_2 is substituted phenyl, the substituent(s) in the phenyl being selected from, methylenedioxy, C_1-C_6 alkylthio, trifluromethyl, trifluoromethoxy, nitrile (-CN), oxo, COR^A,

$CONHR^A$, $-CONR^AR^B$, $-NHR^A$, NR^AR^B, $-NHCOR^C$, $-NHCOOR^A$, $-NR^BCOOR^A$wherein R^A and R^B are independently a C_1-C_6 alkyl group and wherein R^C is a C_2-C_6 alkyl group.

21. (Original) A compound as claimed in claim 19 wherein the compound is selected from any of the compounds as shown in Table 1.

22. (Currently Amended) ~~For use in~~ A therapy comprising administering an effective amount of a compound as claimed in ~~any of claims 19 to 21~~claim 19.

23. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in ~~any of claims 19 to 21~~ claim 19 in combination with a pharmaceutically acceptable carrier or excipients.

24. (Currently Amended) ~~A use as claimed in any of claims 1 to 17 or a~~ The method as claimed in claim ~~18~~ 1 wherein said receptors are adenosine receptors.

25. (Currently Amended) ~~A use as claimed in any of claims 1 to 17 or a~~ The method as claimed in claim ~~18~~ 1 wherein said receptors are adenosine A_{2A} receptors.

26. (Currently Amended) ~~A use as claimed in any of claims 1 to 17 or a~~ The method as claimed in claim ~~18~~ 1 wherein the disorders are selected from movement disorders; acute and chronic pain other than inflammatory pain; anxiety disorders, affective disorders; central and peripheral nervous system degenerative disorders; schizophrenia; cognitive and memory impairment disorders; attention disorders; central nervous system injury; cerebral ischaemia; myocardial ischaemia; muscle ischaemia; sleep disorders; eye disorders; cardiovascular disorders; and diabetes.

27. (Currently Amended) ~~A use or~~The method as claimed in claim 26 wherein the movement disorder is selected from Parkinson's disease, progressive supemuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism and spasticity.

28. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 ~~or claim 27~~, wherein the disorder is a movement disorder and the compound of formula (I) is used or administered together with L-DOPA or a dopamine agonist.

29. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 wherein the anxiety disorder is selected from panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia.

30. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 ~~or claim 27~~ wherein the disorder is pain.

31. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 ~~or claim 27~~ wherein the disorder is neuropathic pain.

32. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 wherein said affective disorder is selected from bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease.

33. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 wherein said central and peripheral nervous system degenerative disorder is selected from corticobasal degeneration, demyelinating disease, Freidrich's ataxia, motoneurone disease, multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathy, systemic lupus erythamatosis, granulomatous disease, olivo-ponto-cerebellar atrophy, progressive pallidal atrophy, progressive supranuclear palsy and spasticity.

34. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 wherein said cognitive and/or memory impairment disorder is selected from dementia, Alzheimers Disease, Frontotemporal dementia, multi-infarct dementia, AIDS dementia, dementia associated with Huntingtons Disease, Lewy body dementia, senife dementia, age-related memory impairment, cognitive impairment associated with dementia, Korsakoff syndrome and dementia pugilans.

35. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 wherein attention disorder is selected from attention-deficit hyperactivity disorder (ADHD), attention deficit disorder, minimal brain dysfunction, brain-injured child syndrome, hyperkinetic reaction childhood and hyperactive child syndrome.

36. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 wherein said central nervous system injury is selected from traumatic brain injury, surgical trauma, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury.

37. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 wherein said cerebral ischaemia is transient ischaemic attack, stroke, subarachnoid haemorrhage, cerebral vasospasm, perinatal asphyxia, drowning, cardiac arrest or subdural haematoma.

38. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 wherein the sleep disorder is selected from hypersomnia, narcolepsy and restless legs syndrome.

39. (Currently Amended) ~~A use or~~ The method as claimed in claim 26 wherein the eye disorder is selected from retinal ischaemia-reperfusion injury and diabetic neuropathy.

40. (Canceled)

41. (Currently Amended) A method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I):



(I)

R_1 is H or NH_2;

R_2 is optionally substituted aryl or heteroaryl attached via a carbon atom;

R_3 is H; optionally substituted C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, or C_3-C_7 cycloalkyl, halogen; OH or OR_{10};

R_4 is H, optionally substituted C_1-C_6alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, C_3-C_7 cycloalkyl, aryl or heteroaryl,

R_5 is H or optionally substituted C_1-C_6 alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, or C_3-C_7 cycloalkyl;

or R_4 and R_5 together form a 5 or 6-membered heterocyclic ring;

R_{10} is optionally substituted C_1-C_6alkyl;

~~as set out in any of claims 1 to 17~~ or a pharmaceutically acceptable salt or prodrug thereof.